Advaxis Inc. [NASDAQ: ADXS] price surged by 13.41 percent to reach at $0.05. The company report on October 15, 2020 that Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020.
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020.
Title: “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC)” Presenter: Dr. Jonathan W. Goldman. University of California Los Angeles, Santa Monica, CAAbstract ID: 360Date and Time: Thursday, November 12th from 4:50 pm until 5:20 pm ET and Saturday, November 14th from 1:00 pm until 1:30 pm ET.
A sum of 3874957 shares traded at recent session while its average daily volume was at 1.24M shares. Advaxis Inc. shares reached a high of $0.469 and dropped to a low of $0.403 until finishing in the latest session at $0.46.
The average equity rating for ADXS stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Advaxis Inc. [ADXS]:
Barclays have made an estimate for Advaxis Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 03, 2016. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on September 22, 2015, representing the official price target for Advaxis Inc. stock. Previously, the target price had yet another raise to $30, while Guggenheim analysts kept a Buy rating on ADXS stock. On June 16, 2015, analysts increased their price target for ADXS shares from 25 to 30.
The Average True Range (ATR) for Advaxis Inc. is set at 0.03, with the Price to Sales ratio for ADXS stock in the period of the last 12 months amounting to 104.62. The Price to Book ratio for the last quarter was 0.90, with the Price to Cash per share for the same quarter was set at 0.35.
ADXS Stock Performance Analysis:
Advaxis Inc. [ADXS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.57. With this latest performance, ADXS shares gained by 3.37% in over the last four-week period, additionally sinking by -24.59% over the last 6 months – not to mention a rise of 31.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADXS stock in for the last two-week period is set at 60.03, with the RSI for the last a single of trading hit 67.37, and the three-weeks RSI is set at 54.28 for Advaxis Inc. [ADXS]. The present Moving Average for the last 50 days of trading for this stock 0.4458, while it was recorded at 0.4147 for the last single week of trading, and 0.6604 for the last 200 days.
Insight into Advaxis Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Advaxis Inc. [ADXS] shares currently have an operating margin of -75.02. Advaxis Inc.’s Net Margin is presently recorded at -79.54.
Return on Total Capital for ADXS is now -49.28, given the latest momentum, and Return on Invested Capital for the company is -52.25. Return on Equity for this stock declined to -52.25, with Return on Assets sitting at -30.90.
Reflecting on the efficiency of the workforce at the company, Advaxis Inc. [ADXS] managed to generate an average of -$474,629 per employee.Advaxis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
ADXS Stock EPS
With the latest financial reports released by the company, Advaxis Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 51.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADXS.
Advaxis Inc. [ADXS] Insider Position Details
There are presently around $3 million, or 25.30% of ADXS stock, in the hands of institutional investors. The top three institutional holders of ADXS stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 3,498,918, which is approximately -3.088% of the company’s market cap and around 0.47% of the total institutional ownership; BLACKROCK INC., holding 870,007 shares of the stock with an approximate value of $0.35 million in ADXS stocks shares; and VANGUARD GROUP INC, currently with $0.33 million in ADXS stock with ownership of nearly 0.733% of the company’s market capitalization.
Positions in Advaxis Inc. stocks held by institutional investors increased at the end of September and at the time of the September reporting period, where 17 institutional holders increased their position in Advaxis Inc. [NASDAQ:ADXS] by around 724,342 shares. Additionally, 13 investors decreased positions by around 485,773 shares, while 12 investors held positions by with 5,954,728 shares. The mentioned changes placed institutional holdings at 7,164,843 shares, according to the latest SEC report filing. ADXS stock had 9 new institutional investments in for a total of 560,898 shares, while 5 institutional investors sold positions of 17,633 shares during the same period.